Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
AKPRO vs BIMATOPROST
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Inhibits P2Y12 platelet receptor, blocking ADP-mediated platelet aggregation.
Bimatoprost is a synthetic prostamide analog that selectively mimics the effects of prostamide F2α. It binds to prostaglandin F (FP) receptors on ciliary muscle cells and trabecular meshwork cells, increasing uveoscleral outflow and possibly trabecular outflow of aqueous humor, thereby reducing intraocular pressure. It also directly stimulates the prostaglandin FP receptor, leading to increased matrix metalloproteinase activity and remodeling of the extracellular matrix in the ciliary body.
Reduction of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI),Off-label: Prevention of stent thrombosis in high-risk PCI patients
Reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension,Hypotrichosis of the eyelashes (off-label use for eyelash growth promotion)
1 drop of 0.45% solution in each eye once daily in the evening or as directed by physician.
One drop of 0.01% or 0.03% ophthalmic solution instilled into the affected eye(s) once daily in the evening.
Terminal elimination half-life: approximately 2-3 hours in aqueous humor; systemic half-life is negligible due to low plasma concentrations.
Terminal half-life: ~45 minutes (intravenous); after topical ocular administration, systemic half-life is similar due to rapid systemic clearance, with clinical effect lasting 24 hours due to ocular tissue binding
Prodrug; metabolized to active metabolite primarily via CYP2C19, with contributions from CYP3A4, CYP2C9, CYP2B6
Bimatoprost is rapidly metabolized via hydrolysis to the more active free acid form by esterases in the cornea and plasma. Further metabolism occurs via oxidation, reduction, and conjugation, primarily in the liver. The major enzymes involved are hepatic cytochrome P450 (CYP) isozymes, with CYP2C9 and CYP3A4 contributing to minor oxidative metabolites. The free acid is subsequently glucuronidated.
Renal excretion of unchanged drug accounts for approximately 1-2% of an administered dose; the remainder is metabolized in ocular tissues and eliminated via nasolacrimal drainage and gastrointestinal tract, with minimal systemic absorption. Biliary/fecal excretion is negligible.
Renal: <67% (unchanged and metabolites), Biliary/fecal: ~25%
Approximately 60-70% bound to plasma proteins, primarily albumin.
~88% bound to albumin
Due to minimal systemic absorption, volume of distribution data is not clinically relevant; for the fraction absorbed, estimated Vd is approximately 0.2-0.4 L/kg.
0.3–0.4 L/kg (indicates distribution primarily into extracellular fluid)
Ocular instillation: systemic bioavailability is low (<1%) due to extensive first-pass metabolism in the nasal mucosa and gastrointestinal tract after nasolacrimal drainage.
Topical ocular: low systemic absorption (~50% absorbed into ocular tissues, with negligible systemic bioavailability due to hydrolysis in plasma)
No specific renal dose adjustments recommended; use with caution in severe renal impairment (Cr Cl <30 m L/min) due to potential systemic accumulation.
No dose adjustment required for renal impairment; no specific GFR-based guidelines.
No specific hepatic dose adjustments recommended; use with caution in severe hepatic impairment (Child-Pugh Class C) due to lack of data.
Use with caution in severe hepatic impairment (Child-Pugh class C); no specific dose adjustments established.
Safety and effectiveness in pediatric patients have not been established; use is not recommended.
Not recommended for use in pediatric patients due to lack of safety and efficacy data.
No specific dose adjustments in elderly; use same as adult dosing, with monitoring for ocular adverse effects.
No specific dose adjustment required; same dosing as adults, but monitor for increased systemic absorption due to age-related ocular surface changes.
Efficacy depends on active metabolite formation; reduced efficacy in CYP2C19 poor metabolizers. Avoid use in patients with active pathological bleeding or history of transient ischemic attack/stroke.
None
Bleeding risk, especially in patients undergoing surgery; thrombotic thrombocytopenic purpura (TTP) reported; premature discontinuation increases cardiovascular event risk; CYP2C19 poor metabolizers may have reduced efficacy.
May cause gradual, permanent changes to eyelashes (increased length, thickness, pigmentation) and periorbital tissue (darkening and deepening of the upper eyelid sulcus). Increased iris pigmentation (iridal melanocytes) is irreversible. Use with caution in patients with hepatic or renal impairment. Risk of macular edema, particularly in aphakic or pseudophakic patients with a torn posterior lens capsule. May exacerbate uveitis or cystoid macular edema. Contains benzalkonium chloride; avoid in patients with hypersensitivity to this preservative. Discontinue if signs of systemic absorption occur (e.g., flushing, hypotension).
Active pathological bleeding (e.g., peptic ulcer, intracranial hemorrhage); history of transient ischemic attack or stroke; severe hepatic impairment; hypersensitivity to AKPRO or any component.
Hypersensitivity to bimatoprost or any component of the formulation. Active intraocular inflammation (e.g., uveitis). Macular edema. Caution in patients with hepatic or renal impairment. Relative contraindication in pregnancy (category C) and breastfeeding.
No known food interactions.
No significant food interactions. No dietary restrictions are required.
Category C. First trimester: Based on animal studies, may cause fetal harm. No adequate human studies. Second and third trimesters: Risk of premature closure of ductus arteriosus and oligohydramnios with NSAID use after 20 weeks gestation.
Bimatoprost is a prostaglandin analog. Animal studies have shown embryofetal toxicity including skeletal malformations and increased post-implantation loss at doses >30 times the human exposure. There are no adequate and well-controlled studies in pregnant women. Risk cannot be ruled out; avoid use in pregnancy unless benefit outweighs risk. First trimester: potential teratogenicity. Second and third trimesters: potential for premature labor or uterine hyperstimulation due to oxytocic effects.
Excreted in breast milk in low amounts (M/P ratio not reported). Use with caution due to potential adverse effects on infant (e.g., gastrointestinal, renal). Short-term use is generally considered acceptable.
Bimatoprost is excreted in rat milk, but no human data exist. The molecular weight (415.57 Da) suggests possible excretion into human breast milk. The M/P ratio is unknown. Because of the potential for serious adverse reactions in nursing infants, especially from systemic effects of prostaglandin analogs, breastfeeding is not recommended during treatment or for 6 hours after ophthalmic administration.
No specific dose adjustment recommended for pregnancy; however, avoid use after 20 weeks gestation due to risks of premature ductus arteriosus closure and oligohydramnios. Use lowest effective dose for shortest duration.
Pregnancy induces physiological changes (increased plasma volume, renal clearance, and hepatic metabolism) that may reduce systemic drug concentrations. For bimatoprost ophthalmic solution, negligible systemic absorption occurs, so no dose adjustment is required. In case of systemic use, close monitoring and potential dose adjustments based on clinical response are warranted, but specific guidelines are unavailable.
AKPRO is a combination ophthalmic solution containing proparacaine 0.5% and fluorescein sodium 0.25%. Use only for diagnostic procedures; never dispense for patient self-administration due to risk of corneal toxicity with repeated use. Apply one drop per eye, then wait 1-2 minutes for maximal anesthesia. Blot excess to reduce systemic absorption. Monitor for corneal epithelial defects after use.
Bimatoprost is a prostaglandin analog used for lowering intraocular pressure (IOP) in open-angle glaucoma or ocular hypertension. It increases uveoscleral outflow. Administer once daily in the evening. Do not exceed once-daily dosing as it may reduce efficacy. Touching the dropper tip to the eye or surrounding structures can contaminate the solution. Remove contact lenses before instillation and wait 15 minutes before reinserting. Common side effects include conjunctival hyperemia, eyelash growth, and periorbital pigmentation. Monitor for cystoid macular edema in aphakic or pseudophakic patients with a torn posterior lens capsule. Use with caution in patients with active intraocular inflammation (e.g., iritis/uveitis).
Do not rub your eyes after the drops are applied, as the anesthetic may mask injury.,This medication is for use in a doctor's office only; do not take it home.,Temporary blurred vision and stinging may occur immediately after the drop.,Avoid driving or operating machinery until vision clears completely.,Inform your doctor if you have a history of corneal disease, glaucoma, or allergies to anesthetics.
Use exactly as prescribed; do not use more than once a day.,Apply in the evening to maximize effectiveness.,Wash hands before and after application.,Remove contact lenses before using and wait 15 minutes before reinserting.,Do not let the dropper tip touch your eye or any surface.,If using more than one eye drop, wait at least 5 minutes between applications.,May cause temporary blurred vision; do not drive until vision clears.,May gradually darken eyelid skin and increase eyelash growth; this is reversible upon discontinuation.,Report any eye pain, vision changes, or signs of infection (redness, swelling) to your doctor.,Store at room temperature away from light and moisture.
No interactions on record
"Azelastine, an antihistamine, may reduce the intraocular pressure-lowering efficacy of bimatoprost, a prostaglandin analog used for glaucoma. This interaction is postulated to occur via antagonism of the prostaglandin F2α receptor or through pharmacodynamic opposition, as antihistamines can interfere with the outflow enhancement mechanism of bimatoprost. Clinically, this may result in inadequate intraocular pressure control, necessitating dose adjustment or alternative therapy."
"Pirfenidone, an antifibrotic agent, may reduce the ocular hypotensive efficacy of bimatoprost, a prostaglandin analog used for glaucoma. This interaction is postulated to occur via pirfenidone's inhibitory effects on prostaglandin synthesis or signaling pathways, potentially attenuating bimatoprost-mediated enhancement of uveoscleral outflow. Clinically, patients may experience inadequate intraocular pressure (IOP) reduction, increasing the risk of glaucoma progression."
"Eprosartan, an angiotensin II receptor blocker (ARB), reduces blood pressure by inhibiting the vasoconstrictor and aldosterone-secreting effects of angiotensin II. Bimatoprost, a prostaglandin analog used for glaucoma, lowers intraocular pressure but can also cause systemic vasodilation, potentially leading to additive hypotensive effects. This interaction may result in excessive lowering of blood pressure, particularly in patients with compromised cardiovascular function or those on multiple antihypertensive agents."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about AKPRO vs BIMATOPROST, answered by our medical review team.
AKPRO is a Prostaglandin Analog (Ophthalmic) that works by Inhibits P2Y12 platelet receptor, blocking ADP-mediated platelet aggregation.. BIMATOPROST is a Prostaglandin Analog that works by Bimatoprost is a synthetic prostamide analog that selectively mimics the effects of prostamide F2α. It binds to prostaglandin F (FP) receptors on ciliary muscle cells and trabecular meshwork cells, increasing uveoscleral outflow and possibly trabecular outflow of aqueous humor, thereby reducing intraocular pressure. It also directly stimulates the prostaglandin FP receptor, leading to increased matrix metalloproteinase activity and remodeling of the extracellular matrix in the ciliary body.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between AKPRO and BIMATOPROST depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of AKPRO is: 1 drop of 0.45% solution in each eye once daily in the evening or as directed by physician.. The standard adult dose of BIMATOPROST is: One drop of 0.01% or 0.03% ophthalmic solution instilled into the affected eye(s) once daily in the evening.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between AKPRO and BIMATOPROST in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. AKPRO is classified as Category C. Category C. First trimester: Based on animal studies, may cause fetal harm. No adequate human studies. Second and third trimesters: Risk of premature closure of ductus arteriosus a. BIMATOPROST is classified as Category C. Bimatoprost is a prostaglandin analog. Animal studies have shown embryofetal toxicity including skeletal malformations and increased post-implantation loss at doses >30 times the h. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.